0000000001331841

AUTHOR

Janet Franklin

showing 3 related works from this author

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

2020

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicineAntibodies BispecificmedicineHumansComplete responsebusiness.industryLymphoma Non-HodgkinHematologymedicine.diseaseLymphomaOncology030220 oncology & carcinogenesisRelapsed refractoryBlinatumomabLymphoma Large B-Cell DiffuseNeoplasm Recurrence LocalbusinessDiffuse large B-cell lymphoma030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.

2019

e19041 Background: Achieving durable response in patients (pts) with relapsed/refractory (R/R) aggressive B-cell lymphoma (B-NHL) is challenging. Blinatumomab, a bispecific T-cell engager (BiTE) immunotherapy targeting CD19-expressing cancer cells, has shown promising efficacy in pts with R/R aggressive B-NHL. We report the durability of complete response (DOCR) in pts treated with blinatumomab. Methods: The DOCR in pts with R/R aggressive B-NHL responding to blinatumomab was assessed using data from two phase 2 studies (study 1 [N = 25], NCT01741792; study 2 [N = 41], NCT02910063) in pts with R/R aggressive B-NHL. CR was assessed using Cheson (study 1) and Lugano (study 2) criteria. Time-…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseaseLymphomaOncologyRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineB-Cell Non-Hodgkin LymphomaBlinatumomabIn patientbusinessComplete responsemedicine.drugJournal of Clinical Oncology
researchProduct

Farmland Biodiversity Monitoring Practice in Europe and North America

2018

Agriculture is one of the main causes for the strong declines in biodiversity over the last decades. To protect and promote farmland biodiversity effectively, politicians and farmers need information about the status and dynamics of biodiversity on agricultural land. We reviewed a number of large monitoring programs in Europe and North America and investigated design decisions, monitoring costs and informative value for stakeholders. Useful programs focus on the landscape scale and investigate the state and dynamics of habitats and one or better several organism groups, mainly plant species and faunal groups if financially feasible. They sample raw data stratified over intensive and remote …

researchProduct